| 2.075 -0.155 (-6.95%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.93  |
1-year : | 13.01 |
| Resists | First : | 7.64 |
Second : | 11.14 |
| Pivot price | 4.08 |
|||
| Supports | First : | 2 |
Second : | 1.66 |
| MAs | MA(5) : | 2.33 |
MA(20) : | 5.46 |
| MA(100) : | 10.23 |
MA(250) : | 8.94 |
|
| MACD | MACD : | -2.1  |
Signal : | -1.8 |
| %K %D | K(14,3) : | 0.9 |
D(3) : | 0.9 |
| RSI | RSI(14): 19.6 |
|||
| 52-week | High : | 15.73 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NXTC ] has closed above bottom band by 24.0%. Bollinger Bands are 93.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.51 - 2.52 | 2.52 - 2.53 |
| Low: | 1.96 - 1.98 | 1.98 - 1.99 |
| Close: | 2.05 - 2.08 | 2.08 - 2.1 |
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Mon, 08 Jun 2026
NextCure Inc stock (US65343E1082): Pipeline focus after restructuring and cash runway update - AD HOC NEWS
Thu, 04 Jun 2026
Cancer experts discuss SIM0505 trial data in on-demand replay - Stock Titan
Mon, 01 Jun 2026
NextCure presents SIM0505 Phase 1 data: 55% ORR in gynecologic cancers; cash runway into Q1 2027 - TradingView
Mon, 01 Jun 2026
Experimental ovarian and uterine cancer drug shows 55% response rate - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 14.8 (%) |
| Held by Institutions | 62.5 (%) |
| Shares Short | 58 (K) |
| Shares Short P.Month | 72 (K) |
| EPS | -16.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.8 % |
| Return on Equity (ttm) | -132.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -15.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|